RESEARCH ARTICLE

Impaired High-Density Lipoprotein Anti-Oxidant Function Predicts Poor Outcome in Critically Ill Patients

Lore Schrutka1, Georg Goliasch1, Brigitte Meyer2, Raphael Wurm1, Lorenz Koller1, Lukas Kriechbaumer3, Gottfried Heinz1, Richard Pacher1, Irene M Lang1, Klaus Distelmaier1*, Martin Hülsmann1☯

1 Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria, 2 Department of Internal Medicine IV, Kaiser-Franz-Josef-Hospital Vienna, Vienna, Austria, 3 University Clinic of Orthopedics, Paracelsus Medical University Salzburg, Salzburg, Austria

☯ These authors contributed equally to this work.
* klaus.distelmaier@meduniwien.ac.at

Abstract

Introduction

Oxidative stress affects clinical outcome in critically ill patients. Although high-density lipoprotein (HDL) particles generally possess anti-oxidant capacities, deleterious properties of HDL have been described in acutely ill patients. The impact of anti-oxidant HDL capacities on clinical outcome in critically ill patients is unknown. We therefore analyzed the predictive value of anti-oxidant HDL function on mortality in an unselected cohort of critically ill patients.

Method

We prospectively enrolled 270 consecutive patients admitted to a university-affiliated intensive care unit (ICU) and determined anti-oxidant HDL function using the HDL oxidant index (HOI). Based on their HOI, the study population was stratified into patients with impaired anti-oxidant HDL function and the residual study population.

Results

During a median follow-up time of 9.8 years (IQR: 9.2 to 10.0), 69% of patients died. Cox regression analysis revealed a significant and independent association between impaired anti-oxidant HDL function and short-term mortality with an adjusted HR of 1.65 (95% CI 1.22–2.24; p = 0.001) as well as 10-year mortality with an adj. HR of 1.19 (95% CI 1.02–1.40; p = 0.032) when compared to the residual study population. Anti-oxidant HDL function correlated with the amount of oxidative stress as determined by Cu/Zn superoxide dismutase (r = 0.38; p<0.001).

Conclusion

Impaired anti-oxidant HDL function represents a strong and independent predictor of 30-day mortality as well as long-term mortality in critically ill patients.
Introduction

Despite intensive research and significant advances in the management of critical ill patients over the last decades, prognosis remains poor [1,2]. Oxidative stress, resulting from an imbalance between reactive oxygen species (ROS) production and anti-oxidant defenses, is known to seriously affect clinical outcome by exacerbating organ damage [3]. Potential sources of increased ROS generation in this highly vulnerable patient population are activated immune cells, the vascular endothelium, the release of iron and copper ions and metalloproteinases, as well as ischaemia/reperfusion-induced tissue injury [3,4]. Increased ROS production during critical illness is accompanied by a disturbance of anti-oxidant systems leading to a severe accumulation of free radicals [4]. This overwhelming oxidative stress response leads to cellular damage through a number of pathways including direct damage to proteins, membranes, DNA and RNA or indirect damage through the activation of pro-inflammatory and pro-apoptotic pathways [4-6]. Consequently, an optimization of anti-oxidant defense is regarded as promising therapeutic approach in patients admitted to the intensive care unit (ICU) [7,8,9].

High-density lipoprotein (HDL) particles possess strong anti-oxidant properties by binding and removing oxidant molecules [10]. Thus HDL is believed to play an important role in scavenging oxidative stress in patients with high levels of oxidative stress. However, there is rising evidence that inflammation and tissue injury, can significantly compromise the protective properties of HDL [11,12]. HDL particles may even amplify pro-oxidant processes in clinical conditions associated with inflammation and oxidative stress [13,14]. A recently published study revealed for the first time a strong association between preserved anti-oxidant capacities of HDL and survival in patients with acute myocardial infarction [14]. This finding is in line with previous studies suggesting that HDL function may relate more to clinical outcome than quantitative serum levels [11,15].

The quality of HDL has not been analyzed in critical ill patients yet. Previous analyses revealed a substantial reduction of HDL serum levels in critical ill patients [16,17]. In view of the underlying inflammatory processes [3,4], it is tempting to speculate that HDL quality is significantly impaired in this highly vulnerable patient population. We therefore analyzed the anti-oxidant capacity of HDL in an unselected cohort of patients admitted to the ICU with a simple serum-based assay, and determined its association with survival.

Materials and Methods

Study Population

We prospectively enrolled all patients admitted to the intensive care unit (ICU) of the Department of Cardiology of the Vienna General Hospital, a university-affiliated tertiary care center, between August 2004 and November 2005 in our study as previously described [18]. Patients aged <18 years were excluded. The study protocol complies with the Declaration of Helsinki and was approved by the Ethics Committee of the Medical University of Vienna; written informed consent was obtained from the patient, patient relatives or the appointed legal guardian.

Baseline characteristics and clinical history were recorded in all patients. According to their primary diagnosis patients were divided into cardiac or non-cardiac patients and further subdivided into postoperative or internal reasons of admission. A non-cardiac patient was defined with a primary non-cardiac diagnosis (e.g. pneumonia) and did not preclude a secondary cardiac disease, nor was a preexisting cardiac disease a priori excluded. All major interventions prior to ICU admittance as well as within the first 48 hours of ICU stay were recorded, as were presence of renal failure and need for extracorporeal renal replacement therapy, mechanical
ventilation, presence of shock and shock category, support therapy with extracorporeal membrane oxygenation, use of intra-aortic balloon counterpulsation, resuscitation, presence of left ventricular dysfunction and heart surgery. Severity of disease was quantified by the Simplified Acute Physiology Score (SAPS) II [19]. Extracorporeal therapy was defined as renal replacement therapy as well as extracorporeal membrane oxygenation at the time of blood sample collection. All-cause 30-day mortality was defined as primary and long-term mortality during the whole observation period as secondary study endpoint. Mortality data were obtained by screening of the national register of death.

**Laboratory measurements**

Routine laboratory assessment was performed in all patients at time of admission according to the local laboratory’s standard procedure. Further blood samples were collected for determination of anti-oxidant HDL-function and measurement of Cu/Zn superoxide dismutase within 24 hours of ICU admission as well as 48h after ICU admission. All samples were stored at -80°C and used for further analyses immediately after thawing.

HDL anti-oxidant capacity was measured using a 2',7'-dichlorodihydrofluorescein diacetate (DCF)-based cell free fluorescent assay that determined the ability of apolipoprotein (apo)-B depleted serum, which includes HDL, apo-A1, apo-A2, and HDL associated particles, to inactivate or aggravate previously oxidized low-density lipoprotein (LDL) [20]. The assay was performed as previously described [14]. Briefly, LDL (Merck, Milipore, Darmstadt, Germany) was diluted in phosphate buffered saline (PBS) to a final cholesterol end-concentration of 100μg/ml and oxidized for 6 hours in 100μM CuSO4 (Merck) at 37°C by dialysis. After HDL containing supernatant was obtained from the patient serum samples by polyethylene glycol depletion (15μl), DCF-DA (final concentration 2.9μg/ml) as well as oxidized LDL (final concentration: 1.4μg/ml) were added to separate wells of 96-well black microplates and incubated at 37°C with PBS to a final volume of 175μl in 96-well plates with clear bottom for one hour (Corning, Amsterdam, Netherlands). The fluorescence signal was measured at an excitation of 485nm and emission wavelength of 530nm using a Synergy H1 Hybrid Microplate Reader (Biotek, Winooski, VT, USA). All patient samples were run in duplicate and a pooled serum control from 3 healthy volunteers was added on each plate. Inter-assay coefficient of variation was 7.8%, whereas intra-assay coefficient of variation was 5.9%. To calculate the HDL oxidant index (HOI), the intensity signal of DCF-fluorescence alone was subtracted from the intensity signal of DCF incubated with apolipoprotein B–depleted patient sera and log-transformed before analysis [13,21]. Accordingly, the higher the HOI the poorer the anti-oxidant function. To correct for inter-assay variability across different plates, a pooled serum control from 3 healthy volunteers was added on each plate, and values for samples from subjects in the study were normalized by this pooled value. Additionally, plasma levels of Cu/Zn superoxide dismutase, a marker for oxidative stress, independent from diabetes mellitus and inflammation [22] were determined using a commercially available ELISA kit (Bender MedSystems, Vienna, Austria. All other laboratory parameters were analyzed according to the local laboratory’s standard procedure at time of study enrollment.

**Statistical analyses**

Discrete data were described by absolute and relative frequencies and compared between groups using Chi-square tests. Because of the asymmetrical distribution, continuous data were presented as medians with interquartile ranges (IQR) and compared between groups using the Mann-Whitney U-tests. Wilcoxon signed-rank tests were applied for pairwise comparison in subgroup analysis. Spearman correlation was performed to assess the relationship between
continuous variables. HOI was stratified into tertiles and the third tertile of HOI has been chosen as cut-off to divide study population into patients with impaired antioxidant HDL function (high HOI) and residual study population. The influence of having high HOI on 30-day mortality as well as long-term mortality was investigated by univariate and multivariable Cox regression models. Multivariate adjustment for potential clinical confounders included the Simplified Acute Physiology Score (SAPS) II [19], age, sex, extracorporeal therapy, cholesterol levels, glomerular filtration rate (GFR) and the use of catecholamines. Kaplan-Meier analyses were applied to measure the effect of HOI on 30-day mortality and long-term mortality and compared using log-rank test. The discriminatory power of the respective variables was assessed using ROC analysis. Two-sided p-values less than 0.05 were used to indicate statistical significance. SPSS 21.0 (SPSS/IBM) was used for all analyses.

Results

Baseline characteristics

A total of 289 patients admitted to the ICU were consecutively enrolled during the initial study period [18]. From 19 patients, no frozen serum samples for determination of anti-oxidant HDL function were available, leaving 270 patients for the final analysis. Sixty-nine percent of patients (n = 187) were male and the median age was 65 years (IQR 55–75). Thirty percent of the study population was post-operatively admitted to the ICU and 67% was hospitalized due to cardiac reasons. Primary diagnoses are summarized in Table 1. The median SAPS-2 score of the study population was 55 (IQR 41–73). Within the first 48 hours of ICU admission, a total of 208 patients (62%) were on catecholamines, 220 patients (82%) required mechanical ventilation, 66 patients (24%) developed acute renal failure, and 29 patients (11%) required renal replacement therapy. Twenty-one patients were treated with intra-aortic balloon counterpulsation, eight patients were on extracorporeal membrane oxygenation support, and three patients had left ventricular or biventricular assist devices. Forty-three patients (16%) were resuscitated before or within 48 hours after ICU admission. According to the baseline HOI, the study population was stratified into patients with impaired anti-oxidant function of HDL, characterized by a high HOI (HOI > 5.90) and residual study population (HOI ≤ 5.90). Detailed baseline characteristics and characteristics for patients with impaired anti-oxidant HDL function and the residual study population are displayed in Table 2. During a median follow-up time of 9.8 years (IQR 9.2–10.0), 69% of patients (n = 185) died. Causes of death were cardiovascular disease (65%), malignancy (14%), lung disease (7%) metabolic disorders (4%), gastrointestinal disease (4%) and other causes (7%).

Association of HDL function with clinical risk factors

Impaired anti-oxidant function of HDL was found significantly associated with higher levels of Cu/Zn superoxide dismutase, a marker of oxidative stress (r = 0.38; p < 0.001). Furthermore, HOI showed an inverse correlation with the GFR (r = -0.17, p = 0.009). Further, sub-analysis revealed a significantly higher HOI in individuals undergoing extracorporeal circulation at the time of blood sample collection (5.93 [IQR 4.96–8.06] vs. 4.88 [IQR 4.02–6.63], p = 0.008). No differences in HOI, determined 48h after ICU admission, were observed between surgical (5.05 [IQR 4.14–7.18]) and non-surgical ICU patients (5.15 [IQR 4.06–6.62] p = 0.577), between patients admitted for cardiac (4.93 [IQR 4.05–6.78]) and non-cardiac reasons (5.30 [IQR 4.23–6.79] p = 0.401) as well as between men (5.03 [IQR 3.97–6.53]) and women (5.46 [IQR 4.30–7.25] p = 0.066). HOI was independent of serum HDL-cholesterol levels (r = 0.017, p = 0.848).

To analyze the changes of anti-oxidant HDL function during the ICU stay, we compared the HOI between serum samples collected on the first day of ICU admission and 48 hours after
ICU admission. HOI was found significantly higher on the first day of ICU admission (5.72 [IQR 4.24–8.75] vs. 5.14 [IQR 4.06–6.79], p<0.001) demonstrating an improvement of anti-oxidant HDL function within the first 48 hours after ICU admission. Sub-analyses revealed

Table 1.

| Primary Diagnosis                        | No. |
|------------------------------------------|-----|
| Cardiac                                  |     |
| Myocardial infarction                    | 28  |
| Cardiogenic shock                        | 20  |
| Heart failure                            | 19  |
| Pulmonary edema                          | 8   |
| Pericardial effusion                     | 7   |
| Arrhythmia                               | 13  |
| Valvular heart disease                   | 8   |
| Coronary artery bypass surgery           | 27  |
| Valve surgery                            | 17  |
| Bypass and valve surgery                 | 9   |
| Cardiac surgery, other                   | 3   |
| Aortic aneurysm                          | 5   |
| Artificial heart                         | 3   |
| Pulmonary hypertension                   | 2   |
| Endocarditis                             | 2   |
| Resuscitation                            | 24  |
| Transplantation                          |     |
| Heart                                    | 4   |
| Lung                                     | 2   |
| Infectious                               |     |
| Sepsis                                   | 7   |
| Neurologic                               |     |
| Stroke                                   | 3   |
| Meningitis                               | 1   |
| Cerebral bleeding                        | 2   |
| Seizure                                  | 1   |
| Coma                                     | 2   |
| Brain death                              | 2   |
| Respiratory                              |     |
| COPD                                     | 11  |
| Respiratory failure                     | 14  |
| Pneumonia                                | 9   |
| Pulmonary embolism                       | 6   |
| Lung Bleeding                            | 1   |
| Oncologic                                |     |
| Esophageal cancer                        | 1   |
| Bronchus carcinoma                       | 1   |
| Bleeding                                 | 5   |
| Cirrhosis hepatis                        | 1   |
| Intoxication                             | 1   |
| Hypothermia                              | 1   |

doi:10.1371/journal.pone.0151706.t001
that improvement of anti-oxidant HDL function within the first 48 hours after ICU admission was only observed in surgical patients (9.26 [IQR 5.24–13.14] vs. 5.11 [IQR 4.24–7.19], p < 0.001), whereas in non-surgical patients a stable HOI was observed (5.35 [IQR 4.04–7.43] vs. 5.14 [IQR 4.03–6.62], p = 0.104).

### Survival analyses

We identified a significant association between high HOI and 30-day mortality with a crude hazard ratio (HR) of 1.73 (95% CI 1.31–2.30; p < 0.001) as well as 10-year long-term mortality with a crude HR of 1.21 (95% CI 1.04–1.41; p = 0.012) when comparing patients with the residual study population. This effect persisted after adjustment for potential confounders with an adjusted HR of 1.65 (95% CI 1.22–2.24; p = 0.001) for 30-day mortality and an adjusted HR of 1.19 (95% CI 1.02–1.40; p = 0.032) for 10-year long-term mortality. The area under the ROC curve (AUC) for HOI was 0.66 for 30-day mortality and 0.55 for 10-year long-term mortality. Kaplan-Meier analysis revealed a significant increase of 30-day mortality (p < 0.001, log-rank test; Fig 1A) and long-term mortality (p = 0.011, log-rank test; Fig 1B) in patients with high

### Table 2. Baseline characteristics of total study population and for patients with impaired anti-oxidant HDL function (HOI > 5.90) and the residual study population (HOI ≤ 5.90).

| N   | Total study population | HOI≤5.90 | HOI>5.90 | P value |
|-----|------------------------|----------|----------|---------|
| HOI (IQR) | 270 | 180 | 90 | <0.001 |
| Age, median years (IQR) | 65 (55–75) | 64 (55–75) | 67 (58–75) | 0.388 |
| Male sex, n (%) | 187 (69) | 131 (73) | 56 (62) | 0.076 |
| Body weight, kg (IQR) | 80 (70–90) | 80 (70–90) | 80 (70–91) | 0.988 |
| MAP, mmHg (IQR) | 58 (49–67) | 59 (53–68) | 57 (45–66) | 0.018 |
| Cholesterol, mg/dl (IQR) | 150 (119–188) | 150 (117–190) | 153 (126–165) | 0.432 |
| HDL-C, mg/dl (IQR) | 37 (31–48) | 37 (29–47) | 42 (33–52) | 0.151 |
| LDL-C, mg/dl (IQR) | 100.20 (71.10–130.10) | 97.20 (66.90–130.10) | 101.60 (79.20–136.40) | 0.509 |
| Cholesterol/HDL quotient (%) | 4.3 (3.4–5.7) | 4.3 (3.4–5.9) | 4.5 (3.4–5.3) | 0.743 |
| Creatinine, mg/dl (IQR) | 1.3 (0.9–1.9) | 1.2 (0.9–1.7) | 1.4 (1.0–2.0) | 0.011 |
| ASAT, U/L (IQR) | 62 (36–158) | 62 (36–148) | 66 (34–210) | 0.543 |
| ALAT, U/L (IQR) | 37 (18–90) | 37 (18–88) | 36 (20–99) | 0.937 |
| γ-GT, U/L (IQR) | 56 (29–114) | 56 (30–112) | 57 (27–121) | 0.816 |
| CRP, mg/dl (IQR) | 3.9 (0.8–12.7) | 3.8 (0.7–11.1) | 3.9 (1.0–17.5) | 0.238 |
| Estimated GFR, ml/min (IQR) | 59.67 (39.41–85.31) | 64.12 (40.21–95.74) | 53.37 (33.50–74.57) | 0.019 |
| Catecholamines, n (%) | 208 (77) | 135 (75) | 73 (81) | 0.154 |
| SAPS II, points (IQR) | 55 (41–73) | 53 (40–66) | 64 (45–80) | 0.001 |
| Extracorporeal circulation, n (%) | 35 (13) | 17 (9) | 18 (20) | 0.015 |
| Extracorporeal membrane oxygenation, n (%) | 8 (3) | 3 (1) | 5 (6) | 0.076 |
| Haemodiafiltration, n (%) | 29 (11) | 14 (8) | 15 (17) | 0.028 |
| Postoperative admission to ICU, n (%) | 80 (30) | 51 (28) | 29 (32) | 0.510 |
| Cardiac admission, n (%) | 181 (67) | 123 (68) | 58 (64) | 0.522 |
| Length of ICU stay, days (IQR) | 6 (3–12) | 6.5 (4–12) | 4.5 (2–13) | 0.052 |

doi:10.1371/journal.pone.0151706.t002
HOI. Survival was decreased in patients with high HOI after 30 days (31% vs. 12%) and after 10 years (76% vs. 65%) compared to the residual study population.

**Discussion**

In the present study, we analyzed for the first time the protective properties of HDL in critically ill patients and identified a strong association between anti-oxidant HDL function and clinical outcome. Short-term as well as 10-year long-term survival was significantly reduced in patients with impaired anti-oxidant HDL function reflected by a high HOI. These associations were even more pronounced after adjustment for potential confounders. Anti-oxidant HDL function, determined 48 hours after ICU admission, was selected as risk predictor in order to await the initial massive stress response associated with the ICU admission [23].

So far, the role of HDL was not in the focus of previous research in ICU patients. Although a reduction of HDL serum levels has been described in critical ill patients [16,17], the quality of HDL has never been investigated. This lack of HDL research in ICU patients is primarily caused by the former assumption that the main function of HDL is restricted to the reverse cholesterol transport. However, over the last years it has become evident that HDL particles possess anti-oxidant, anti-inflammatory, anti-thrombotic and anti-apoptotic properties besides reverse cholesterol transport [24]. Considering the pivotal role of oxidative stress and inflammation during critical illness [3,4], these properties of HDL may significantly affect clinical outcome. Consequently, HDL has gained more attention in the acute clinical setting over the last years [5,13,14]. In patients with acute myocardial infarction significantly impaired HDL function have been found [13,14,25] strongly associated with increased mortality [14]. Our results are the first to demonstrate an association between anti-oxidant HDL function and clinical outcome in a heterogeneous population of acutely ill patients, including surgical and non-surgical patients.
There exists strong evidence that oxidative stress dramatically increases during critical illness, specifically in patients with sepsis, cardiovascular disorders, cardiogenic shock, organ dysfunction, acute respiratory distress syndrome, acute renal failure, and disseminated intravascular coagulation [26,27,28]. Activated phagocytic cells, the vascular endothelium, and ischaemia/reperfusion-induced tissue injury have been identified as potential sources of oxidative stress. Oxidative stress results in damage to proteins, membranes, DNA and RNA [4] and has been found associated with severity and progress of disease in critical ill patients [28,29]. An increase of ROS levels were found accompanied by a decrease in anti-oxidant defenses [30]. Consequently, the prevention and control of ROS production is suggested to be a potential therapeutic target in ICU patients.

The present study revealed a strong association between survival and anti-oxidant HDL function in a highly vulnerable ICU patient population. In patients with poor anti-oxidant HDL function, higher levels of oxidative stress were measured. Furthermore, patients with impaired anti-oxidant HDL function showed a trend towards longer ICU stays. These findings underline the essential role of HDL in the anti-oxidant defense. The underlying pathophysiological mechanisms for impaired anti-oxidant function of HDL have not been fully elucidated yet but there is strong evidence that changes in HDL protein composition and protein quality are crucially involved [31]. These structural changes of HDL particles may be provoked by an acute stress response during conditions of infection, inflammation or tissue injury [32]. Furthermore, oxidative stress itself is known to trigger post-translational modifications of HDL-associated proteins that may render HDL dysfunctional [32,33]. Particularly, myeloperoxidase (MPO), which is mainly secreted by activated neutrophils, has been identified to affect HDL function by promoting oxidative damage on HDL associated proteins [33–35]. Similarly, replacement of apolipoprotein A1 by serum amyloid A on the surface of the HDL particle and altered enzymatic activities, including paraoxonase-1 and platelet-activating factor acetylhydrolase, might contribute to the impairment of anti-oxidant HDL function [36,37]. There is rising evidence that the lipid composition of the HDL particle is also important for HDL functions. Sphingosine-1-phosphate (S1P), a component of the HDL particle, has been recently demonstrated to be a cause of HDL dysfunction; low S1P levels induce HDL dysfunction, and S1P-loading the HDL particle corrects this HDL dysfunction [38,39]. The crucial role of S1P is underlined by a recently published study showing a significant reduction of oxidative stress by administrating S1P agonists in a porcine model of ischemia-reperfusion [40].

In agreement with previous analyses [14], the observed loss of anti-oxidant HDL function occurred independently of HDL cholesterol serum levels. HDL particles are suggested to be more relevant for cardioprotective functions of HDL than the absolute concentration of HDL cholesterol [21]. Analyses of clinical risk factors identified reduced kidney function as strongly associated with impaired anti-oxidant HDL function. This finding is in line with prior studies [41] and might be caused by higher inflammatory and oxidative stress levels in patients with reduced GFR [42]. Furthermore, our study identified a poor anti-oxidant HDL function in patients exposed to extracorporeal circulation (ECC), including renal replacement therapy as well as ECMO support. The underlying mechanisms remain unclear but a systemic stress response triggered by the artificial surface of ECC is known to induce excessive generation of ROS [43,44]. On the other hand, the ECC circuit may adsorb trace elements that are essential to the anti-oxidant response, specifically zinc and selenium [44,45]. Further subgroup analysis revealed significantly higher HOI at the first day of ICU admission compared to samples collected 48 hours after ICU admission. Further analyses revealed that these differences in HOI were mainly influenced by the high HOI of surgical patients at ICU admission, which significantly improved within 48 hours. A strong inflammatory stress reaction with peak responses occurring 12 to 24 hours after surgery might explain this observation [46].
In summary, the identification of impaired anti-oxidant HDL function as independent risk factor for poor clinical outcome complements the knowledge on risk stratification in critically ill patients. This suggests that anti-oxidant properties of HDL rather than total HDL serum levels should be considered for risk stratification. Interestingly, data on favorable effects of anti-oxidant therapies on clinical outcome in ICU patients are controversially discussed so far [7,8,9]. Results of the current study propose that restoration and maintenance of anti-oxidant HDL function might serve as a new additional therapeutic target in critically ill patients. Considering the persistent effect of impaired anti-oxidant HDL function on clinical outcome, high-risk patients might benefit from specific treatment not only during the ICU stay but also in close and long-term check-ups after hospital discharge. A recently published study suggests that statin therapy may improve anti-oxidant HDL function [13]. If future randomized clinical trials confirmed this finding, statins might become a promising therapeutic option in critically ill patients. In addition to medical treatment, intensified exercise training in ICU survivors might be a potential therapeutic approach, as exercise is known to have beneficial effects on HDL functions [47]. Whether early physical therapy interventions in the ICU might have favorable impact on protective functions of HDL has to be addressed by future studies.

A potential limitation of the present study is that the applied assay for determining the anti-oxidant HDL function has been performed with apolipoprotein B–depleted serum samples instead of using freshly isolated HDL. However, previous studies demonstrated that the use of apolipoprotein B–depleted serum samples provides valid and reproducible results as long as this technique is consistently applied for all measurements [48,49]. The patients under investigation represent a specific critically ill study population and it remains to be tested whether findings could be transferred to a more general patient population.

Conclusion
We identified impaired anti-oxidant HDL capacity as a strong and independent predictor of short-term as well as long-term mortality in unselected critically ill patients. Reduced renal function and exposure to extracorporeal circulation were found associated with compromised anti-oxidant HDL function.

Author Contributions
Conceived and designed the experiments: LS L. Koller L. Kriechbaumer KD IML GH MH BM RP. Performed the experiments: LS KD GG MH RW BM. Analyzed the data: LS GG KD MH RP L. Koller L. Kriechbaumer. Contributed reagents/materials/analysis tools: LS KD MH RP L. Koller L. Kriechbaumer RW. Wrote the paper: LS L. Koller L. Kriechbaumer GG RP GH IML KD.

References
1. Damuth E, Mitchell JA, Bartock JL, Roberts BW, Trzeciak S (2015) Long-term survival of critically ill patients treated with prolonged mechanical ventilation: a systematic review and meta-analysis. Lancet Respir Med 3: 544–553. doi: 10.1016/S2213-2600(15)00150-2 PMID: 26003390
2. Graf J, Muhlhoff C, Doig GS, Reinartz S, Bode K, Dujardin R, et al. (2008) Health care costs, long-term survival, and quality of life following intensive care unit admission after cardiac arrest. Crit Care 12: R82. doi: 10.1186/cc6893 PMID: 18638367
3. Crimi E, Sica V, Slutsky AS, Zhang H, Williams-Ignarro S, Ignarro LJ, et al. (2006) Role of oxidative stress in experimental sepsis and multisystem organ dysfunction. Free Radic Res 40: 665–672. PMID: 16983993
4. Goodyear-Bruch C, Pierce JD (2002) Oxidative stress in critically ill patients. Am J Crit Care 11: 543–551; quiz 552–543. PMID: 12425405
5. Hori M, Nishida K (2009) Oxidative stress and left ventricular remodelling after myocardial infarction. Cardiovasc Res 81: 457–464. doi: 10.1093/cvr/cvn335 PMID: 19047340

6. Wraith KS, Magwenzi S, Aburima A, Wen Y, Leake D, Naseem KM (2013) Oxidized low-density lipoproteins induce rapid platelet activation and shape change through tyrosine kinase and Rho kinase-signaling pathways. Blood 122: 580–589. doi: 10.1182/blood-2013-04-394168 PMID: 23699602

7. Hardy G, Hardy I, Manzanares W (2012) Selenium supplementation in the critically ill. Nutr Clin Pract 27: 21–33. doi: 10.1177/0884533611434116 PMID: 22307489

8. Adabag AS, Ishani A, Bloomfield HE, Ngo AK, Wilt TJ (2009) Efficacy of N-acetylcysteine in preventing renal injury after heart surgery: a systematic review of randomized trials. Eur Heart J 30: 1910–1917. doi: 10.1093/eurheartj/ehp053 PMID: 19282300

9. Lassnig A, Punz A, Barker R, Keznickl P, Manhart N, Roth E, et al. (2003) Influence of intravenous vitamin E supplementation in cardiac surgery on oxidative stress: a double-blinded, randomized, controlled study. Br J Anaesth 90: 148–154. PMID: 12538369

10. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM (2004) Anti-inflammatory properties of HDL. Circ Res 95: 764–772. PMID: 15486323

11. Khra AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, et al. (2011) Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 364: 127–135. doi: 10.1056/NEJMoa1001689 PMID: 21226578

12. Sorrentino SA, Besler C, Rohrer L, Meyer M, Heinrich K, Bahmann FH, et al. (2010) Endothelial-vaso-protective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation 121: 110–122. doi: 10.1161/CIRCULATIONAHA.108.836346 PMID: 20026785

13. Patel PJ, Khra AV, Jafri K, Wilensky RL, Rader DJ (2011) The anti-oxidative capacity of high-density lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease. J Am Coll Cardiol 58: 2068–2075. doi: 10.1016/j.jacc.2011.08.030 PMID: 22051328

14. Distelmaier K, Schrutka L, Seidl V, Winter M, Wurm R, Mangold A, et al. (2015) Impaired anti-oxidant HDL function is associated with premature myocardial infarction. Eur J Clin Invest 45: 731–738. doi: 10.1111/ejci.12317 PMID: 25831998

15. Rohatgi A, Khra A, Berry JD, Givens EG, Ayers CR, Wedin KE, et al. (2014) HDL Cholesterol Efflux Capacity and Incident Cardiovascular Events. N Engl J Med.

16. van Leeuwen HJ, Heezius EC, Dallinga GM, van Strijp JA, Verhoef J, van Kessel KP (2003) Lipoprotein metabolism in patients with severe sepsis. Crit Care Med 31: 1359–1366. PMID: 12771603

17. Gordon BR, Parker TS, Levine DM, Saal SD, Wang JC, Sloan BJ, et al. (2001) Relationship of hypolipidemic agents to cytokine concentrations and outcomes in critically ill surgical patients. Crit Care Med 29: 1563–1568. PMID: 11505128

18. Meyer B, Huelsmann M, Wexberg P, Delle Karth G, Berger R, Moertl D, et al. (2007) N-terminal pro-B-type natriuretic peptide is an independent predictor of outcome in an unselected cohort of critically ill patients. Crit Care Med 35: 2268–2273. PMID: 17717488

19. Le Gall JR, Lemeshow S, Saulnier F (1993) A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 270: 2957–2963. PMID: 8254858

20. Navab M, Hama SY, Hough GP, Subbanagounder G, Reddy ST, Fogelman AM (2001) A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res 42: 1308–1313. PMID: 11483633

21. Distelmaier K, Wiesbauer F, Blessberger H, Oravec S, Schrutka L, Binder C, et al. (2015) Impaired anti-oxidant HDL function is associated with premature myocardial infarction. Eur J Clin Invest 45: 731–738. doi: 10.1111/ejci.12466 PMID: 25989880

22. Pawlak K, Pawlak D, Mysliwiec M (2005) Cu/Zn superoxide dismutase plasma levels as a new useful clinical biomarker of oxidative stress in patients with end-stage renal disease. Clin Biochem 38: 700–705. PMID: 15963971

23. Cuesta JM, Singer M (2012) The stress response and critical illness: a review. Crit Care Med 40: 3283–3289. doi: 10.1097/CCM.0b013e31826567eb PMID: 22975887

24. Navab M, Reddy ST, Van Lenten BJ, Fogelman AM (2011) HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol 8: 222–232. doi: 10.1038/nrcardio.2010.222 PMID: 21304474

25. Rivamoto M, Rohrer L, Roschitzki B, Besler C, Mocharla P, Mueller M, et al. (2013) Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling. Circulation 127: 891–904. doi: 10.1161/CIRCULATIONAHA.112.108753 PMID: 23349247
26. Himmelfarb J, McMonagle E, Freedman S, Kienzak J, McMenamin E, Le P, et al. (2004) Oxidative stress is increased in critically ill patients with acute renal failure. J Am Soc Nephrol 15: 2449–2456. PMID: 15339994
27. Griendling KK, Ushio-Fukai M (1998) Redox control of vascular smooth muscle proliferation. J Lab Clin Med 132: 9–15. PMID: 9665366
28. Metnitz PG, Barton C, Fischer M, Fridrich P, Steltzer H, Druml W (1999) Antioxidant status in patients with acute respiratory distress syndrome. Intensive Care Med 25: 180–185. PMID: 10193545
29. Alonso de Vega JM, Diaz J, Serrano E, Carbonell LF (2002) Oxidative stress in critically ill patients with systemic inflammatory response syndrome. Crit Care Med 30: 1782–1786. PMID: 12163793
30. Oldham KM, Bowen PE (1998) Oxidative stress in critical care: is antioxidant supplementation beneficial? J Am Diet Assoc 98: 1001–1008. PMID: 9739800
31. Shao B, Pennathur S, Heinecke JW (2012) Myeloperoxidase targets apolipoprotein A-I, the major high density lipoprotein protein, for site-specific oxidation in human atherosclerotic lesions. J Biol Chem 287: 6375–6386. doi: 10.1074/jbc.M111.337345 PMID: 22219194
32. Shah AS, Tan L, Long JL, Davidson WS (2013) Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond. J Lipid Res 54: 2575–2585. doi: 10.1194/jlr.R035725 PMID: 23434634
33. Huang Y, DiDonato JA, Levison BS, Schmitt D, Li L, Wu Y, et al. (2014) An abundant dysfunctional apolipoprotein A1 in human atheroma. Nat Med 20: 193–203. doi: 10.1038/nm.3459 PMID: 24464187
34. Hewing B, Parathath S, Barrett T, Chung WK, Astudillo YM, Hamada T, et al. (2014) Effects of native and myeloperoxidase-modified apolipoprotein a-I on reverse cholesterol transport and atherosclerosis in mice. Arterioscler Thromb Vasc Biol 34: 779–789. doi: 10.1161/ATVBHA.113.303044 PMID: 24407029
35. Zheng L, Nukuna B, Brennan ML, Sun M, Goormastic M, Settle M, et al. (2004) Apolipoprotein A-I as a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 114: 529–541. PMID: 15314690
36. Kontush A, Chapman MJ (2006) Antiatherogenic small, dense HDL—guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med 3: 144–153. PMID: 16505860
37. Nobecourt E, Jacqueminet S, Hansel B, Chantepie S, Grimaldi A, Chapman MJ, et al. (2005) Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia. Diabetologia 48: 529–538. PMID: 15729582
38. Sattler K, Graler M, Keul P, Weske S, Reimann CM, Jindrova H, et al. (2015) Defects of High-Density Lipoproteins in Coronary Artery Disease Caused by Low Sphinogosine-1-Phosphate Content: Correction by Sphinogosine-1-Phosphate-Loading. J Am Coll Cardiol 66: 1470–1485. doi: 10.1016/j.jacc.2015.07.057 PMID: 26403344
39. Badimon JJ, Santos-Gallego CG (2015) HDL Dysfunction: Is the Answer in the Sphinx’s Riddle? J Am Coll Cardiol 66: 1486–1488. doi: 10.1016/j.jacc.2015.08.008 PMID: 26403345
40. Santos-Gallego CG, Vahl TP, Goliasch G, Picatoste B, Arias T, Ishikawa K, et al. (2016) The Sphinogosine-1-Phosphate Receptor Agonist Fingolimod Increases Myocardial Salvage and Decreases Adverse Post-Infarction Left Ventricular Remodeling in a Porcine Model of Ischemia-Reperfusion. Circulation. 134: 1485–1498. doi:10.1016/j.cir.2015.07.057 PMID: 26282592
41. Dounousi E, Papavasiliou E, Makedou A, Ioannou K, Katopodis KP, Tselepis A, et al. (2012) Serum amyloid A in uremic HDL promotes inflammation. J Am Soc Nephrol 23: 934–947. doi: 10.1681/ASN.2011070668 PMID: 22282592
42. Rouleau GA, Pouliotte V, Talajic M (1999) Clinical importance of plasma antioxidant status in critically ill patients. Curr Opin Crit Care 5: 5-12. doi: 10.1097/00063173-199901000-00002 PMID: 9980084
43. Dounousi E, Papavasiliou E, Makedou A, Ioannou K, Katopodis KP, Tselepis A, et al. (2006) Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis 48: 752–760. PMID: 17059994
44. Laffey JG, Boylan JF, Cheng DC (2002) The systemic inflammatory response to cardiac surgery: implications for the anesthesiologist. Anesthesiology 97: 215–252. PMID: 12131125
45. McDonald CI, Fung YL, Fraser JF (2012) Antioxidant trace element reduction in an in vitro cardiopulmonary bypass circuit. ASAIO J 58: 217–222. doi: 10.1097/MAT.0b013e31824cc856 PMID: 22460776
46. Shekar K, Roberts JA, McDonald CI, Fisquet S, Barnett AG, Mullany DV, et al. (2012) Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenation. Crit Care 16: R194. doi: 10.1186/cc11679 PMID: 23068416
47. Adams V, Besler C, Fischer T, Riwanto M, Noack F, Hollriegel R, et al. (2013) Exercise training in patients with chronic heart failure promotes restoration of high-density lipoprotein functional properties. Circ Res 113: 1345–1355. doi: 10.1161/CIRCRESAHA.113.301684 PMID: 24059733
48. Kelesidis T, Currier JS, Huynh D, Meriwether D, Charles-Schoeman C, Reddy ST, et al. (2011) A biochemical fluorometric method for assessing the oxidative properties of HDL. J Lipid Res 52: 2341–2351. doi: 10.1194/jlr.D018937 PMID: 21957198

49. Kelesidis T, Reddy ST, Huynh D, Meriwether D, Fogelman AM, Navab M, et al. (2012) Effects of lipid-probe interactions in biochemical fluorometric methods that assess HDL redox activity. Lipids Health Dis 11: 87. doi: 10.1186/1476-511X-11-87 PMID: 22768920